Consistent with our study, a number of studies demonstrated that combination therapy would be more efficient to inhibit acquired resistance in the process of development and showed better survival benefit.21, 30, 31 Studies of recent development and obstacles of melanoma with BRAF and MEK inhibition as MAPK pathway inhibitor significantly overcame acquired resistance and had a higher survival rate and a more durable response rate.32, 33 It had been reported that combination of MEK and BRAF inhibition had improved the quality of life of patient with metastatic melanoma.34 Here, MAP2K7 is linked to metastatic melanoma.